Discovery of morpholine-based aryl sulfonamides as Nav1.7 inhibitors
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 28 (5) , 958-962
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical IndicationsJournal of Medicinal Chemistry, 2015
- Global Nav1.7 Knockout Mice Recapitulate the Phenotype of Human Congenital Indifference to PainPLOS ONE, 2014
- No Gain, No Pain: NaV1.7 as an Analgesic TargetACS Chemical Neuroscience, 2014
- The NaV1.7 sodium channel: from molecule to manNature Reviews Neuroscience, 2012
- Neurological perspectives on voltage-gated sodium channelsBrain, 2012
- Loss-of-function mutations in sodium channel Nav1.7 cause anosmiaNature, 2011
- A stop codon mutation in SCN9A causes lack of pain sensationHuman Molecular Genetics, 2007
- Loss‐of‐function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populationsClinical Genetics, 2007
- An SCN9A channelopathy causes congenital inability to experience painNature, 2006
- Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgiaJournal of Medical Genetics, 2004